Cerity Partners’s Dianthus Therapeutics DNTH Stock Holding History

Cerity Partners’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,250	Closed	-$28K	–	1496
2022 Q3	$28K	Hold	1,250	–	–	﹤0.01%	1157
2022 Q2	$24K	Hold	1,250	–	–	﹤0.01%	1163
2022 Q1	$58K	Hold	1,250	–	–	﹤0.01%	915
2021 Q4	$89K	Hold	1,250	–	–	﹤0.01%	986
2021 Q3	$146K	Sell	1,250 -375	-23%	-$43.7K	﹤0.01%	662
2021 Q2	$254K	Hold	1,625	–	–	0.01%	631
2021 Q1	$308K	Hold	1,625	–	–	0.01%	550
2020 Q4	$204K	Hold	1,625	–	–	0.01%	594
2020 Q3	$177K	Hold	1,625	–	–	0.01%	473
2020 Q2	$195K	Hold	1,625	–	–	0.01%	425
2020 Q1	$163K	Hold	1,625	–	–	0.01%	413
2019 Q4	$394K	Buy	+1,625	New	+$304K	0.02%	378

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cerity Partners's DNTH Position: Q4 2022 in Review

Cerity Partners sold out of Dianthus Therapeutics (DNTH) in Q4 2022, closing a stake of 1,250 shares — an estimated $28K sold.

Cerity Partners first reported a position in DNTH in Q4 2019 and held it in 12 quarters. The position peaked at $394K in Q4 2019. 53 funds tracked by Wall St. Rank hold DNTH as of Q4 2022.

Cerity Partners reported no remaining Dianthus Therapeutics position as of Q4 2022 after selling out during the quarter.
Cerity Partners sold 1,250 Dianthus Therapeutics shares in Q4 2022, an estimated $28K.
Cerity Partners first reported a position in Dianthus Therapeutics in Q4 2019 and held it in 12 quarters.
Cerity Partners's Dianthus Therapeutics position peaked at $394K in Q4 2019.
53 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2022.

Based on Cerity Partners's 13F filing for Q4 2022, filed 15 Feb 2023.